Last Sunday morning, I took my 2-year-old son to a zoo.
There were zebras, camels, and a kid-sized train that took him on a “safari.” Not bad, considering we were just an hour away from New York City.
There was just one problem: the zoo wasn’t as socially distanced as I might have liked. So when I saw a sign for Covid-19 testing on the drive home, it caught my eye.
It was a cold day, and the line at the walk-in clinic stretched for blocks. There were old men, people in wheelchairs, families with young kids — and they sure weren’t 6 feet apart.
I pulled over to the curb, rolled down the window, and asked about the wait. “Two hours so far,” said a tattooed kid with a skateboard who was about halfway to the door. Ouch.
Against that backdrop, I’d like to tell you about a startup you could invest in today…
It’s a healthcare startup offering at-home testing for Covid-19 and chronic diseases.
If it’s successful, it could potentially become very valuable. So let’s get to it…
Conventional healthcare today is failing us. Consider:
- 84% of an estimated 40 million pre-diabetics aren’t even aware they’re at risk.
- Chronic disease causes 7 of 10 deaths.
- Medical expenses are the #1 cause of bankruptcy in the U.S.
The fact is, traditional check-ups and lab visits just aren’t doing enough to identify disease, or to help lower the health risk of those who might be prone to certain conditions.
Furthermore, in an effort to reduce human exposure in the midst of Covid-19, people who should be going for health checks aren’t doing so.
But recently, an alternative has emerged…
The alternative is at-home lab testing.
This is a way for consumers like you to take a lab test at home (generally, by taking a pinprick of blood), and then send it to a lab for results.
In 2019, the market for at-home lab testing reached $300 million, up 50% from the year prior.
But because of COVID-19, this market is exploding right now…
And a new startup is aiming to become one of its leaders.
Introducing: Choose Health
Choose Health is a health-tracking startup that provides at-home lab testing.
Developed by physicians, it helps individuals take control of their health — without going to a clinic or hospital.
Here’s how it works:
- Users take a health survey online and then order tests. Tests start at $68.
- A “health kit” arrives in the mail so users can collect a sample at home.
- Users send the sample to a lab, and get results and recommendations within days.
Here’s what its health kit looks like:
As you can see, in addition to testing for Covid-19, people can test for “health markers” such as visceral fat, insulin sensitivity, inflammation, cholesterol, and blood sugar.
If a test reveals signs of a chronic disease, a user can take steps to alleviate their condition.
Healthcare and Biotech Are Exploding
Choose Health has good revenue traction, a solid team, and the wind at its back.
Now it’s raising about $1 million so it can grow more quickly. The minimum investment is $100, the valuation is $5 million, and the round is open to all investors.
If it’s successful, it could become incredibly valuable. (As a point of reference, thanks to the potential in this market, the blood-testing startup Theranos was at one time valued at $10 billion.)
Keep in mind: I’m not recommending that you go and blindly invest in Choose Health. This is an early-stage venture, and substantial research would need to be done prior to making an investment decision.
But in the midst of Covid-19, healthcare and biotech companies are exploding right now.
(In fact, as Lou Basenese has been writing about for several weeks, these sectors keep hitting all-time highs. And if you’re joining Lou’s “Stock Market Tracking Number” presentation this afternoon, you’ll learn about 3 specific biotech companies he expects to soar.)
So if you’re looking to profit from the emerging trend of At-Home Health Testing, Choose Health is certainly worth a look!
Please note: Crowdability has no relationship with any of the startups we write about. We’re an independent provider of education and research on startups and alternative investments.